Publications by authors named "M Retz"

Claim this Profile
N
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, Bogdan Żurawski, Philippe Barthélémy, Margitta Retz

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
Matthias Michael Heck, Jan Lehmann, Thomas Amiel, Herbert Rübben, Peter Albers, Margitta Retz

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice].
Margitta Retz, Angelika Borkowetz, Katja Wittenzellner, Heja Aga-Barfknecht, Gunhild von Amsberg

Aktuelle Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
J N Graff, M Burotto, P C Fong, D W Pook, B Zurawski, M Retz

Ann Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.
C Gratzke, M Özgüroğlu, A Peer, M A N Sendur, M Retz

Ann Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis